The optimal therapeutic serum trough level (Ctrough) of adalimumab was defined between 3,5
and 7,0 µg/ml in patients with plaque type psoriasis. An adalimumab Ctrough above this
therapeutic range did not add clinical response. Based on this therapeutic window, the
introduction of dose adjustments based on Ctroughs (therapeutic drug monitoring) will be
further validated in a prospective randomized-controlled trial. Here, we aim to determine
whether, in patients with a good clinical response and supratherapeutic adalimumab Ctroughs,
dose reduction is able to maintain favorable clinical outcome.